Secukinumab for Giant Cell Arteritis
John H. Stone, Nils Venhoff, Frank Buttgereit, Christian Dejaco et autres
BACKGROUND: Glucocorticoids (GCs) are standard treatment for giant cell arteritis (GCA). Many patients experience relapses or GC-related toxicity. Secukinumab, a fully human monoclonal antibody that selectively inhibits interleukin-17A, is being studied as additional therapy for GCA. METHODS: GCAptAIN was a randomized, parallel-group, …
us, de, at, it, es, ch, be, fr, au, dk, in, cn (code pays fourni par la source)
4 citations
NEJM Evidence